Xeris Biopharma Holdings Statistics
Total Valuation
XERS has a market cap or net worth of $1.23 billion. The enterprise value is $1.40 billion.
Important Dates
The last earnings date was Thursday, November 6, 2025, before market open.
| Earnings Date | Nov 6, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XERS has 165.92 million shares outstanding. The number of shares has increased by 8.48% in one year.
| Current Share Class | 165.92M |
| Shares Outstanding | 165.92M |
| Shares Change (YoY) | +8.48% |
| Shares Change (QoQ) | +11.39% |
| Owned by Insiders (%) | 4.36% |
| Owned by Institutions (%) | 54.73% |
| Float | 158.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 64.61 |
| PS Ratio | 4.36 |
| Forward PS | 3.61 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 123.59 |
| P/OCF Ratio | 116.77 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 49.90, with an EV/FCF ratio of 140.24.
| EV / Earnings | n/a |
| EV / Sales | 5.26 |
| EV / EBITDA | 49.90 |
| EV / EBIT | 87.97 |
| EV / FCF | 140.24 |
Financial Position
The company has a current ratio of 1.93
| Current Ratio | 1.93 |
| Quick Ratio | 1.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | 6.90 |
| Debt / FCF | 25.83 |
| Interest Coverage | 0.54 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 2.88% |
| Return on Invested Capital (ROIC) | 3.98% |
| Return on Capital Employed (ROCE) | 6.26% |
| Revenue Per Employee | $675,475 |
| Profits Per Employee | -$39,695 |
| Employee Count | 394 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 0.73 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +122.46% in the last 52 weeks. The beta is 0.92, so XERS's price volatility has been similar to the market average.
| Beta (5Y) | 0.92 |
| 52-Week Price Change | +122.46% |
| 50-Day Moving Average | 8.39 |
| 200-Day Moving Average | 5.76 |
| Relative Strength Index (RSI) | 31.22 |
| Average Volume (20 Days) | 2,903,953 |
Short Selling Information
The latest short interest is 17.85 million, so 10.76% of the outstanding shares have been sold short.
| Short Interest | 17.85M |
| Short Previous Month | 17.44M |
| Short % of Shares Out | 10.76% |
| Short % of Float | 11.25% |
| Short Ratio (days to cover) | 7.73 |
Income Statement
In the last 12 months, XERS had revenue of $266.14 million and -$15.64 million in losses. Loss per share was -$0.10.
| Revenue | 266.14M |
| Gross Profit | 225.04M |
| Operating Income | 15.90M |
| Pretax Income | -15.64M |
| Net Income | -15.64M |
| EBITDA | 28.04M |
| EBIT | 15.90M |
| Loss Per Share | -$0.10 |
Full Income StatementBalance Sheet
The company has $91.60 million in cash and $257.65 million in debt, giving a net cash position of -$166.06 million or -$1.00 per share.
| Cash & Cash Equivalents | 91.60M |
| Total Debt | 257.65M |
| Net Cash | -166.06M |
| Net Cash Per Share | -$1.00 |
| Equity (Book Value) | -861,000 |
| Book Value Per Share | -0.01 |
| Working Capital | 107.82M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $10.56 million and capital expenditures -$583,000, giving a free cash flow of $9.98 million.
| Operating Cash Flow | 10.56M |
| Capital Expenditures | -583,000 |
| Free Cash Flow | 9.98M |
| FCF Per Share | $0.06 |
Full Cash Flow StatementMargins
Gross margin is 84.56%, with operating and profit margins of 5.98% and -5.88%.
| Gross Margin | 84.56% |
| Operating Margin | 5.98% |
| Pretax Margin | -5.88% |
| Profit Margin | -5.88% |
| EBITDA Margin | 10.53% |
| EBIT Margin | 5.98% |
| FCF Margin | 3.75% |
Dividends & Yields
XERS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.48% |
| Shareholder Yield | -8.48% |
| Earnings Yield | -1.27% |
| FCF Yield | 0.81% |
Analyst Forecast
The average price target for XERS is $9.43, which is 26.92% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.43 |
| Price Target Difference | 26.92% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 23.38% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XERS has an Altman Z-Score of -0.2 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.2 |
| Piotroski F-Score | 6 |
